NCT07101549View on ClinicalTrials.gov

Treating Nectin-4-positive Advanced Solid Tumors With R-Star001 (Nectin-4-CART-IL18)

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2028

Conditions
Advanced Solid Tumors
Interventions
DRUG

R-Star001

"Drug: Nectin-4-targeted CAR T-cell injection with inducing IL-18 secretion (R-Star001).~The trial consists of a traditional '3 + 3' pattern dose-escalation phase and a dose-expansion phase."

Trial Locations (1)

518100

Cancer Hospital Chinese Academy Of Medical Sciences,Shenzhen Center, Shenzhen

All Listed Sponsors
lead

changjianhua

OTHER

NCT07101549 - Treating Nectin-4-positive Advanced Solid Tumors With R-Star001 (Nectin-4-CART-IL18) | Biotech Hunter | Biotech Hunter